Cohort study identifies predictors for retinopathy in hypertensive pregnancy disorders.
This was a cohort study conducted at two hospitals from December 2020 to December 2025. The population included 667 patients with hypertensive disorders of pregnancy (PIH), split into a development cohort (n=400), an internal validation cohort (n=267), and an external validation cohort (n=200). The study examined predictors for the primary outcome of retinopathy, comparing a group with specific hypertensive disorder predictors to a non-retinopathy group.
In the modeling group, the incidence of retinopathy was 28.0% (112/400). Several factors were identified as independent risk factors for retinopathy: HDP onset 3 weeks (OR = 11.548), proteinuria (+++) (OR = 14.535), hematocrit >0.35 (OR = 16.733), and systolic blood pressure (OR = 1.143). No p-values or confidence intervals were reported for these associations.
Safety and tolerability data were not reported, including adverse events, serious adverse events, or discontinuations. The study did not report follow-up duration, funding, conflicts of interest, or practice relevance. Key limitations include the observational design, which cannot establish causality, and the lack of reported statistical uncertainty measures.
Given these limitations, the findings suggest potential predictors for retinopathy in hypertensive pregnancy disorders, but they should not be used to guide causal interventions. Further research is needed to validate these associations and assess clinical applicability.
View Original Abstract ↓
Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis
Evolocumab cuts heart events in high-risk diabetes patients
Related in Cardiology
From Other Specialties
